Orchard Therapeutics plc (ORTX)の価格はいくらですか

Orchard Therapeutics plc (ORTX)の価格は$16.70です

Orchard Therapeutics plc (ORTX)の時価総額は何ですか

Orchard Therapeutics plc (ORTX)の時価総額は$210.34Mです

Orchard Therapeutics plc（ORTX）の株価履歴

Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing gene-based treatments for severe and often fatal rare conditions, operating across the United Kingdom, European Union, and the United States. Their innovative gene therapy strategy involves modifying a patient's own hematopoietic stem cells, converting them into a therapeutic cellular drug that can address the illness with just one dose. The company markets Strimvelis, a gammaretroviral therapy approved for treating adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Orchard's clinical pipeline features several investigational therapies, including OTL-101 for ADA-SCID, OTL-200 targeting metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Early-stage research programs encompass OTL-203 for mucopolysaccharidosis type I, OTL-201 for MPS-IIIA, and OTL-202 for MPS IIIB. Furthermore, a strategic partnership with Pharming Group N.V. covers the research, development, production, and commercialization of OTL-105, an experimental ex vivo autologous hematopoietic stem cell gene therapy designed for hereditary angioedema. Established in 2015 as Orchard Rx Limited, Orchard Therapeutics plc is headquartered in London, UK.

年	パフォーマンス
2024	2.11%
2023	292.95%
2022	-67.24%
2021	-72.13%
2020	-65.44%
2019	-7.87%
2018	0.00%

年

パフォーマンス

2024

2.11%

2023

292.95%

2022

-67.24%

2021

-72.13%

2020

-65.44%

2019

-7.87%

2018

0.00%

企業	株価	変化率 1年%	国
Vertex Pharmaceuticals Incorporated VRTX.US	$556.43	40.29%	US
Argenx SE ARGX.US	$1.05K	45.39%	NL
Moderna, Inc. MRNA.US	$152.82	535.43%	US
CSL Limited CSL.AX	$123.39	-8.70%	AU
Lonza Group AG LONN.SW	$757.71	6.76%	CH

企業

株価

変化率 1年%

国